MB Funds to sup­port the growth of Phar­ma­to­ry

Phar­ma­to­ry has joined forces with MB Funds, the lead­ing Finnish pri­vate equi­ty investor, to fur­ther devel­op its activ­i­ties for the ben­e­fit of our cus­tomers and col­lab­o­ra­tion part­ners.

With the sup­port of MB Funds, Phar­ma­to­ry plans to expand its oper­a­tions into rapid­ly grow­ing high poten­cy API (“HPA­PI”) mar­ket by invest­ing in HPA­PI facil­i­ty set-up.

‘I’m hap­py to share an impor­tant mile­stone for Phar­ma­to­ry. We tru­ly wel­come MB Funds as an investor and part­ner. This is more than a finan­cial invest­ment — it is a shared view on what we are build­ing and where we are going. From the very first con­ver­sa­tions it was clear that we aligned on vision, ambi­tion, and val­ues. With MB Funds’s expe­ri­ence and sup­port, we are in a strong posi­tion to accel­er­ate growth and cre­ate even more val­ue for our clients. This invest­ment rep­re­sents a sig­nif­i­cant mile­stone on our 25-year-long jour­ney, and we could not have cho­sen a bet­ter part­ner for the next phase. Phar­ma­to­ry remains ful­ly com­mit­ted to deliv­er­ing the excep­tion­al qual­i­ty and client expe­ri­ence in the future too. I’m grate­ful to every­one who has been part of get­ting us this far — the best still lies ahead,’ states Dr. Jaana Kar­jalainen, CEO and a found­ing mem­ber of Phar­ma­to­ry.

‘Phar­ma­to­ry oper­ates in a high­ly attrac­tive small mol­e­cule API CDMO mar­ket and holds a rep­u­ta­tion for high sci­en­tif­ic know-how, agile client-cen­tric ser­vices, qual­i­ty and effec­tive project man­age­ment. The com­pa­ny has very capa­ble man­age­ment with strong expe­ri­ence from inter­na­tion­al oper­a­tions and an orga­ni­za­tion with deep chem­istry exper­tise. Phar­ma­to­ry is well-posi­tioned to expand into size­able and rapid­ly grow­ing high poten­cy API CDMO mar­ket, sup­port­ed by very robust under­ly­ing trends, and MB Funds is excit­ed to sup­port company’s growth,’ com­ments Anssi Mat­ti­la, part­ner of MB Funds.

The invest­ment will focus on con­struc­tion of a new man­u­fac­tur­ing area along with the sup­port­ing infra­struc­ture with­in the exist­ing indus­tri­al premis­es. This enables a broad­er spec­trum of ser­vices, espe­cial­ly for the high poten­cy API GMP man­u­fac­tur­ing mar­ket, in the near future.

‘The entire Phar­ma­to­ry team is excit­ed, and we are con­fi­dent that this col­lab­o­ra­tion will bring clear ben­e­fits to our clients and fur­ther enhance the ser­vices they have come to rely on over the years. The part­ner­ship with MB Funds and the new board mem­bers strength­en our jour­ney and give us great sup­port for our next phase of growth,’ com­ments Dr. Heik­ki Has­si­la, Busi­ness Devel­op­ment Direc­tor of Phar­ma­to­ry.

Pharmatory’s board will be strength­ened by Dr. Knut Ring­bom, for­mer CEO and one of the founders of Biov­ian, and Arto Toivo­nen, M.Sc. (Chem.Eng.), for­mer Pres­i­dent of Fermi­on and Busi­ness Devel­op­ment Direc­tor of Ori­on. Ring­bom and Toivo­nen will also become share­hold­ers of Phar­ma­to­ry togeth­er with the man­age­ment and MB Funds. Anssi Mat­ti­la serves as Chair of the Board of Phar­ma­to­ry, and the oth­er mem­bers are Meri Koivu­la, Knut Ring­blom and Arto Toivo­nen.

About Phar­ma­to­ry

Phar­ma­to­ry, found­ed in 2001, pro­vides ser­vices for glob­al phar­ma and biotech com­pa­nies in med­i­cine devel­op­ment with CDMO offer­ing for human and vet­eri­nary phar­ma­ceu­ti­cals. The company’s ser­vice offer­ing includes ana­lyt­i­cal, process R&D, and con­tract man­u­fac­tur­ing ser­vices accord­ing to Good Man­u­fac­tur­ing Prac­tice (GMP). The company’s oper­a­tions are based on long-term part­ner­ships with its clients. Phar­ma­to­ry has facil­i­ty in Oulu, Fin­land, with a team of high­ly skilled and expe­ri­enced pro­fes­sion­als in the field of chem­istry. 

Con­tact per­sons

Anssi Mat­ti­la
Part­ner, MB Funds
anssi.mattila@mb.fi

Jaana Kar­jalainen
CEO, Phar­ma­to­ry Oy
jaana.karjalainen@pharmatory.com     

Source: Phar­ma­to­ry